Current Research Studies

SC-N188 Views and Outcomes with Immune effector Cell therapy (VOICE)

SC-N188 VOICE

  • Condition(s): Multiple Myeloma, Other Digestive Organ, Non-malignant Disease, Other Respiratory and Intrathoracic Organs, Other Female Genital, Kidney, Leukemia, other, Myeloid and Monocytic Leukemia, Soft Tissue, Thyroid, Colon, Hodgkin's Lymphoma, Lip, Oral Cavity and Pharynx, Anus, Urinary Bladder, Pancreas, Unknown Sites, Other Urinary, Corpus Uteri, Other Hematopoietic, Kaposi's Sarcoma, Esophagus, Brain and Nervous System, Stomach, Larynx, Rectum, Lymphoid Leukemia, Small Intestine, Breast, Mycosis Fungoides, Prostate, Ill-Defined Sites, Melanoma, Skin, Bones and Joints, Cervix, Other Skin, Ovary, Liver, Lung, Non-Hodgkin's Lymphoma, Eye and Orbit, Other Male Genital, Other Endocrine System
  • Phase: N/A
  • Clinicaltrials.gov ID: NA

What is the goal of the study?

This is a longitudinal study of patient-reported outcomes of children, adolescents, and young adults receiving immune effector cell (e.g., CAR-T) therapy at Seattle Children's Hospital. Participants will be asked to complete surveys at 7 longitudinal timepoints around immune effector cell therapy related to physical symptoms and psychosocial functioning. Data from this study will provide us with patient and caregiver perspectives of experiences with this novel therapy. Findings may help inform how we counsel patients receiving immune effector cell therapy in the future and also lead to innovative clinician-facing symptom monitoring interventions.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: